Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy
© Wong et al; licensee BioMed Central Ltd. 2011
Received: 13 April 2011
Accepted: 17 June 2011
Published: 17 June 2011
RNA processing plays a critical role in the replication of HIV-1, regulated in part through the action of host SR proteins. To explore the impact of modulating SR protein activity on virus replication, the effect of increasing or inhibiting the activity of the Cdc2-like kinase (CLK) family of SR protein kinases on HIV-1 expression and RNA processing was examined.
Despite their high homology, increasing individual CLK expression had distinct effects on HIV-1, CLK1 enhancing Gag production while CLK2 inhibited the virus. Parallel studies on the anti-HIV-1 activity of CLK inhibitors revealed a similar discrepant effect on HIV-1 expression. TG003, an inhibitor of CLK1, 2 and 4, had no effect on viral Gag synthesis while chlorhexidine, a CLK2, 3 and 4 inhibitor, blocked virus production. Chlorhexidine treatment altered viral RNA processing, decreasing levels of unspliced and single spliced viral RNAs, and reduced Rev accumulation. Subsequent experiments in the context of HIV-1 replication in PBMCs confirmed the capacity of chlorhexidine to suppress virus replication.
Together, these findings establish that HIV-1 RNA processing can be targeted to suppress virus replication as demonstrated by manipulating individual CLK function and identified chlorhexidine as a lead compound in the development of novel anti-viral therapies.
The dependence of HIV-1 replication on the appropriate balance of its RNA processing suggests that this step in the virus lifecycle might be an attractive target for therapeutic intervention [1–3]. From a single 9 kb transcript, over 40 mRNAs are generated by a process of suboptimal splicing that generates three classes of HIV-1 mRNAs: unspliced (US) RNA used to produce Gag and Gagpol proteins; singly spliced (SS) mRNAs encoding Vif, Vpr, Vpu or Env; and multiply spliced (MS) mRNAs used to synthesize Rev, Tat or Nef. Both Tat and Rev play central roles in the replication of HIV-1. Tat increases abundance of all viral RNAs by increasing elongation efficiency of RNA polymerase II on proviral DNA [4, 5] while Rev promotes the transport of unspliced and singly spliced viral RNAs to the cytoplasm [6, 7]. Consequently, factors which alter the extent of HIV-1 RNA splicing can have dramatic effects on the extent of viral replication; undersplicing resulting in the loss of Tat and Rev while oversplicing reduces the abundance of incompletely spliced RNAs so that there is insufficient Gag and Env protein for new virion assembly. Understanding how to manipulate conditions within the cell to alter the extent of HIV-1 RNA splicing could provide insights into new strategies to control this infection.
Studies to date have identified a number of cis- and trans-acting factors involved in regulating HIV-1 RNA splicing [1, 2]. Examination of the four splice donors and eight splice acceptors, used in generating the complete spectrum of viral mRNAs, demonstrated that much of the regulation is due to the suboptimal nature of the sequences that comprise the 3' splice sites (3'ss). Mutations that optimize the splice sites result in dramatic shifts in usage, increasing the extent of viral RNA splicing and reducing HIV-1 replication [8, 9]. Use of specific 3'ss is also regulated by the presence of exon splicing silencers (ESSs) and exon splicing enhancers (ESEs) that act in an antagonistic fashion to suppress or promote, respectively, the use of particular splice sites. The majority of HIV-1 ESSs function by binding of hnRNP A1, which promotes addition of further hnRNP A1 molecules to adjacent sequences and thereby sterically blocks interaction of U2 snRNP and U2AF with the branchpoint and polypyrimidine tract [10–14]. The ESEs counter the ESSs by the binding of specific members of the SR protein family. SR proteins consist of one or two N-terminal RNA binding motifs and a C-terminus rich in arginine-serine dipeptides which collaborate to promote the use of adjacent splice sites by stabilizing interaction of splicing factors (such as U2AF, U1 snRNP) with the splice site signals . In some instances, binding to an ESE also occludes interaction of factors with the adjacent/overlapping ESS [13, 16]. The significance of these factors in regulating HIV-1 RNA processing has been illustrated by examining the effect of mutating the cis elements in viral RNA or altering SR protein expression levels in cells. Mutations which inactivate the ESS near the vpr reading frame (ESSV) resulted in both a significant increase in use of the adjacent 3' splice site (splice acceptor 2, SA2) but also a marked decrease in unspliced viral RNA abundance leading to a loss of virus replication . Similarly, mutations in Env have been identified that activate a cryptic splice through recruitment of the SR protein SRSF2 (SC35) and hnRNP H . In addition, overexpression of the SR protein SRSF1(SF2/ASF) has been shown to increase use of the 3'ss for Vpr (SA2) while increased levels of SRSF2/SRFS7 (9G8) induce use of the 3'ss for Tat (SA3) [19–21].
The sensitivity of HIV-1 RNA processing to changes in abundance or activity of SR proteins has suggested that these factors could be targeted to achieve changes in the nature and/or extent of viral RNA splicing so as to inhibit HIV-1 replication. Support for this hypothesis can be found in the observation that HIV-1 infection is associated with changes in SR protein phosphorylation/abundance that could be reversed upon overexpression of SR protein kinase 2 (SRPK2) [22–24]. Several proteins have been shown to phosphorylate SR proteins, with members of the SR protein kinase (SRPK1 and SRPK2) and Cdc2 like kinase (CLK1, CLK2, CLK3 and CLK4) families being the most intensively studied . Comparison of SRPK and CLK kinases have revealed that, while both can phosphorylate SR proteins, they differ in the extent of phosphorylation and in the protein sequences modified [26–29]. This fact, coupled with differences in subcellular localization (SRPKs are cytoplasmic while CLKs are nuclear), suggests that they play distinct roles in regulating SR protein activity [30–33].To explore the role of SR kinases other than SRPK2 in regulating HIV-1 gene expression, we examined the impact of overexpressing members of the CLK family on viral RNA abundance and protein synthesis. The four members of the CLK family (CLK1/Sty, CLK2, CLK3 and CLK4) have overlapping specificity for the phosphorylation of specific SR proteins . Despite a significant degree of homology between the various CLK members, we observed that they had disparate effects on HIV-1 expression; CLK1 promoting expression of HIV-1 Gag while CLK2 dramatically suppressed synthesis of viral structural proteins. Effects at the protein level were mirrored in alterations in viral RNA abundance, suggesting that CLK1 and CLK2 act to modulate HIV-1 RNA processing in distinct ways. Based on these observations, we also explored the effects of recently described CLK inhibitors (TG003, chlorhexidine) on HIV-1 replication [34, 35]. Similar to the results with the individual CLKs, we observed that the two inhibitors had markedly different effects on viral gene expression: TG003 treatment had no effect while chlorhexidine significantly suppressed HIV-1 Gag synthesis. In context of HIV-1 growth in PBMCs, chlorhexidine also suppressed virus replication. Given that chlorhexidine is currently used in humans at doses ~1000 fold greater than used in our assays, our findings suggest that this compound could be used at mucosal surfaces to prevent virus transmission.
CLK1 Increases While CLK2 Decreases HIV-1 Gene Expression
Chlorhexidine Inhibits CLK2, 3 and 4 Function and Alters HIV-1 RNA Processing
Chlorhexidine Treatment Inhibits HIV-1 Rev Accumulation
Chlorhexidine is an Inhibitor of HIV-1 Replication in PBMCs
Previous studies on the regulation of RNA processing have clearly outlined the important role of SR proteins in modulating usage of particular splicing sites . Consequently, modulating RNA processing could be achieved by either regulating the abundance of specific SR proteins or modulating their activity through changes in the extent of their phosphorylation [43, 44]. Either hyper- or hypo-phosphorylation of SR proteins has been shown to alter their ability to support RNA splicing in vitro and results in changes in alternative splicing choices [25–33, 45]. Previous analysis of the role played by SRPK2 in controlling HIV-1 gene expression determined that its overexpression increased virus production putatively by modulating the activity of SRp75 . Our findings on the effect of CLK overexpression on HIV-1 replication revealed that overexpression of individual CLKs had very distinct effects on HIV-1 RNA processing and gene expression. This point is best illustrated by comparison of CLK1 with CLK2. While CLK1 overexpression resulted in increased HIV-1 Gag RNA levels and protein synthesis, CLK2 overexpression led to dramatic suppression of HIV-1 Gag production associated with reduced accumulation of all viral RNAs (US, SS and MS). Differences between the various CLKs occurred despite comparable expression and their indistinguishable effects on SRSF2 subnuclear distribution (Figures 1 and 2). Previous analyses had demonstrated that altering CLK expression levels modified a number of alternative splicing events but, in most instances, changing expression of different CLKs had the same effect on the RNA splicing event being monitored [46–48]. Consequently, our observation of marked differences in effect of individual CLKs on HIV-1 is one of the first demonstrations of distinct activities between these individual family members. The contrasting effects of CLK2 versus the kinase inactive CLK2 KR (acting as a dominant negative) on HIV-1 expression confirm that the effects observed are due to kinase activity and not simply overexpression of the protein.
The basis for the differences between the various CLKs is presently unclear. Preliminary analysis of changes in SR protein phosphorylation upon overexpression of different CLKs revealed increased levels of SR protein phosphorylation but no differences in the SR proteins modified (data not shown). Consequently, differences may reflect differing extents of phosphorylation or modifications of specific residues within SR proteins. Alternatively, given that CLKs have been shown to interact with proteins outside of the SR protein family, the different activities could reflect phosphorylation of other host factors [36, 49–52].
Similar to the differential responses to the overexpression of individual CLKs, the two CLK inhibitors tested also yielded very distinct effects. TG003 inhibits predominately CLK1 and CLK4, with reduced effect on CLK2 but had little to no effect on HIV-1 gene expression. In contrast, chlorhexidine, which blocked HIV-1 Gag and Rev synthesis, is a potent inhibitor of CLK3 and 4 with reduced activity against CLK2 as measured by its capacity to reverse CLK-induced effects on SRSF2 subnuclear distribution . The fact that both drugs have overlapping activity against the various CLKs but yield strikingly different effects on virus expression suggests that the regulation of HIV-1 is due to the effect of chlorhexidine on CLK3 function alone, alterations in the relative activities of the individual CLKs present, or possibly modulation of another host factor. Altering relative activities among the individual CLKs by overexpression or drug inhibition could account for the inhibitory effects on HIV-1 gene expression.
Subsequent evaluation of the basis for chlorhexidine suppression of HIV-1 gene expression/replication indicated that the response is distinct from that seen upon overexpression of CLK2 or 3, as indicated by their effects on viral RNA accumulation. CLK3 overexpression had a limited effect on viral RNA abundance and CLK2 overexpression repressed accumulation of all HIV-1 RNAs. In contrast, chlorhexidine induced a shift in viral RNA accumulation, reducing levels of US and SS RNAs while increasing MS RNA levels. Such a response is suggestive of an enhancement of the overall splicing of HIV-1 RNAs given that subsequent analysis did not detect any shift in splice site usage. In addition, chlorhexidine selectively reduced Rev protein expression without any change in Tat (p16) levels. In the absence of any reduction in Rev RNA abundance, it would appear that chlorhexidine also selectively inhibits Rev RNA translation or reduces the stability of this protein. Whatever the mechanism, the reduced levels of Rev account for the loss of p24 (Gag) seen since Rev is essential to the export and translation of the corresponding viral US and SS RNAs.
In summary, our experiments have highlighted the different activities among members of the CLK family in the regulation of HIV-1 gene expression and RNA processing. This finding suggests that these kinases likely selectively modulate alternative RNA splicing in the context of other genes. More significantly, we have demonstrated that small molecule inhibitors of specific CLKs can suppress HIV-1 gene expression and replication. Given that the process affected by chlorhexidine is distinct from those targeted by current HIV-1 therapeutics (i.e. entry, reverse transcription, integration, virus maturation), these findings highlight the feasibility of targeting viral RNA processing as a novel strategy to control HIV-1 replication that could be used in concert with current drug combinations to enhance the control of this infection . Chlorhexidine is already in use in humans as the active ingredient in mouthwash and topical antiseptics at doses (~2 mM) 1000 fold above those required to block HIV-1 replication. While the observed toxicity of chlorhexidine in the context of PBMCs precludes its systemic use, its application on mucosal surfaces is well tolerated in humans suggesting the use of chlorhexidine as a microbicide to block HIV-1 transmission at the site of entry (mucosal surfaces) by inhibiting virus replication in the local region or reducing the level of virus secretion at these surfaces in those already infected. A better understanding of the mechanism of chlorhexidine/CLK2 action will likely provide greater insights that could guide the development of additional compounds with improved specificity and activity.
Materials and methods
Plasmids and cell tranfections
To explore the effects of CLKs on HIV-1 protein expression/RNA, HeLa cells stably transduced with an inducible Tet-On HIV-1 system were used [41, 42]. Activation of HIV-1 gene expression was achieved by either addition of doxycyline (Dox) at a concentration of 2 μg/ml or transfection with the constitutively active Tet activator, tTA. Modification of the published HIV Tet-ON system consisted of deleting the RT and IN genes by Mls1 digestion and using the resulting construct to generate the HeLa rtTA HIVΔmls cell line by retroviral transduction and cloning (Figure S1). To explore the effect of CLK overexpression on HIV-1 gene expression, cells were transfected with empty expression plasmid (CMVmyc 3xterm) or vectors expressing GFP-CLK1, GFP-CLK2, GFP-CLK3, GFP-CLK4 (provided by J. Bell, University of Ottawa) or GFP-CLK2 KR (provided by S. Stamm, University of Kentucky) along with CMVtTA to induce provirus expression in cells taking up DNA. Transfections were performed using polyethylene imine (PEI, Polysciences Inc.). Cells and media were harvested 48 h post-transfection to assess effects on HIV-1 gene expression.
In the case of drug treatment, cells were seeded onto 6-well plates at approximately 0.5 × 106 cells per well (~50-75% confluence) in IMDM with 10% FBS and antibiotics (1 × Pen-Strep, 100 μg/mL, 1 × Amphotericin B, 0.5 μg/mL) (Wisent Corporation). Drugs were obtained from Sigma-Aldrich (Chlorhexidine, cat. #C6143)) or provided by Masatoshi Hagiwara (TG003/TG009, Tokyo Medical & Dental University) and solubilized to 10 mM with DMSO. After 4-5 hours of drug treatment, HIV expression was induced by addition of doxycycline (2 μg/ml final concentration). After approximately 24 hours, cell supernatants were harvested for p24 ELISA, while cells were harvested for RNA or protein analyses. Cell viability was monitored by either trypan blue exclusion (Gibco) or XTT assay (Sigma-Aldrich) .
Analysis of HIV-1 protein expression
For analysis of HIV-1 (Gag) protein expression, media was adjusted to 1% Triton X-100 and assayed by p24 ELISA as described in the HIV-1 p24CA antigen capture assay kit (AIDS & Cancer virus Program, NCI-Frederick, Frederick, MD, USA).
Quantitation of HIV-1 mRNA Levels
Cells were harvested by incubation in 2 mM EDTA-PBS for 15 minutes at 37°C and pelleted cells used in RNA purification or protein analysis. RNA was purified by Aurum Total RNA Mini Kits (Bio-Rad, Cat. #732-6820). Purified RNA was reverse transcribed using M-MLV (Invitrogen, Cat. #28025-013). cDNAs reactions (20 μl) were diluted to 150 μL and used in qRT-PCR analysis of HIV-1 mRNA levels using the standard curve method. Each reaction was set-up as follows: 0.4 μL of Taq DNA polymerase (5 U/μL, NEB, Cat. #M0267L), 2.5 μL of ThermolPol buffer, 2.5 μL of 10X SYBR Green I (Sigma-Aldrich, Cat. #S9430), 2.5 μL of 2.5 mM dNTPs, 1.0 μL of 5' primer (0.1 ug/uL), and 1.0 μL of 3' primer (0.1 μg/μL), 10.1 μL H2O, and 5 μL of cDNA. The forward and reverse primers used in the quantitation of HIV-1 mRNA are shown below: unspliced (US), 5' - GAC GCT CTC GCA CCC ATC TC - 3' and 5' - CTG AAG CGC GCA CGG CAA - 3'; singly spliced (SS), 5' - GGC GGC GAC TGG AAG AAG C - 3' and 5' - CTA TGA TTA CTA TGG ACC ACA C - 3'; and multiply spliced (MS), 5' - GAC TCA TCA AGT TTC TCT ATC AAA - 3' and 5' - AGT CTC TCA AGC GGT GGT - 3'. Results were normalized to the housekeeping gene, ß-actin, which served as an internal loading control. 5'-GAGCGGTTCCGCT GCCCTGAGGCACTC-3' and 5'-GGGCAGTGATCTCCTTCTGCATCCTG-3'. qRT-PCRs were run on an Eppendorf Mastercycler ep realplex4. The cycle conditions used for US, MS, and Actin were 95°C, 2 min followed by 40 cycles of 95°C, 15s; 60°C, 15s; and 72°C, 15s. SS conditions were 95°C, 2 min followed by 40 cycles of 95°C, 30s; 55°C, 30s; and 72°C, 30s.
Analysis of HIV-1 alternative splicing
The effect of CLKs and drugs on HIV-1 splice site usage was performed as previously described . cDNAs were analyzed for changes in splice site usage within the 2 kb, MS RNA class. The forward and reverse primers are as followed: 5'-GGGCAGTGATCTCCTTCTGCATCCTG -3' and 5' -TCA TTG CCA CTG TCT TCT GCT CT - 3'. Initial rounds of cold RT-PCR were set-up as followed: 1 μL cDNA, 1 μL of Taq DNA polymerase, 5 μL of 10X ThermolPol buffer, 4 μL of 2.5 mM dNTPs, 10 μL of forward primer (10 μM), 10 μL of reverse primer (10 μM), and 19 μL of H2O in a 50 μL final reaction volume. Thermocycler conditions used were 95°C, 2 min followed by 34 cycles of 95°C, 1 min; 57°C, 1 min; and 68°C, 1 min; and ended with 68°C, 5 min; and 4°C, indefinitely. A second round of radioactive PCR was run with the following changes/additions to the conditions described above: 3 μL of diluted cDNA from the first PCR reaction (1/10th dilution), 0.5 μL of α-32P-dCTP (Perkin Elmer, #BLU013A250UC), and 16.5 μL of H2O. The same thermocycler conditions were also used except only 5 cycles were run. An equal volume of loading buffer (90% formamide, 10 mM EDTA, 0.025% xylene cyanol, and 0.025% bromophenol blue) was added to the products and heated at 95°C for 5 minutes prior to loading onto sequencing gels (6% polyacrylamide, 8 M Urea, 1xTBE), and products detected by phosphoimager. Densitometry was performed using ImageJ by density plots generated for each lane. Values for each HIV-1 RNA specie(s) detected were divided by the total density from all viral RNA species in a sample (fraction of total RNA).
Western blot analysis of HIV-1 proteins
Cells pellets were solubilized in 100 to 300 uL of RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), incubated at 95°C for 5 minutes, and centrifuged for 2 minutes at 12 K × g. Lysate supernatants were quantitated by Bradford assay. For Western blotting, equal amounts of protein were run on 7, 10 or 12% SDS-PAGE, transferred to PVDF (0.45 μm, Perkin-Elmer, Cat. #NEF1002) by electrophoretic transfer and blots blocked in 5% Milk-PBS-T (0.05% Tween-20, 1xPBS) for 1 h at room temperature. For Rev, blots were probed with a 1/250 dilution of mouse monoclonal (Rev-6) antibody to HIV-1 Rev (Abcam, Cat. #ab85529) in PBS-T. For α-Tubulin, blots were washed then probed with mouse monoclonal α-Tubulin antibody (Sigma-Aldrich, Cat. #T9026) diluted to 1/5000 in PBS-T. For Tat, blots were probed with a 1/5000 dilution of rabbit polyclonal antibody to HIV-1 Tat (Abcam, Cat. #ab43014) in 5% Milk-PBS-T. After primary antibody incubations, blots were washed in PBS-T and then incubated with a 1/5000 dilution of isotype-specific HRP-conjugated secondary antibody in 5% Milk-PBS-T available from Jackson ImmunoResearch (Cat. #715-036-150 for rabbit and Cat. #711-036-152 for mouse). After washes, blots were developed using Western Lightning ECL (Perkin-Elmer, Cat. #NEL101) and exposed to autoradiography film.
Effect of drugs on CLK kinase modulation of SR protein subnuclear distribution
Cells were transfected with vectors expressing GFP-tagged CLK1, CLK2, CLK3 or CLK4. Two days post-transfection, cells were either treated with DMSO, TG003 or chlorhexidine for 4-5 h or overnight prior to fixation in 4% paraformaldehyde, 1xPBS. Cells were subsequently permeabilized by treatment with 1% Triton X-100, 1xPBS followed by blocking in 3% BSA, 1xPBS for 1 h. Subcellular distribution of SRSF2 (SC35) was determined by staining with a mouse anti-SRSF2 (SC35) antibody (BD Sciences) followed by incubation with a Texas Red-labeled donkey anti-mouse antibody (Jackson Immunoresearch). Cells were stained with DAPI prior to mounting to detect nuclei. Images were captured using a Leica DMR microscope.
HIV-1 infection of PBMCs
Blood was isolated from HIV seronegative donors, leukapheresed, and stored at -80°C. PBMCs were isolated from blood of healthy donors using Ficoll-Hypaque (VWR, Cat. #CA95038-170L as detailed by manufacturer. For infections, 1 mL of cells (100 × 106) were thawed, diluted in R-2 (RPMI containing 2% FBS) and centrifuged at 300 RCF for 10 minutes at room temperature. Thawed cells were cultured at 37°C in R-10 or RPMI complete medium (10% FBS (heat-inactivated), 1% GlutaMAX-1 (Invitrogen, Gibco, Cat. #35050-061), 1x Pen-Strep (100 μg/mL; Wisent Corp.), and 1 × Amphotericin B (0.5 μg/mL; Wisent Corp.), containing 2 μg/mL of PHA-L (Sigma, Cat. #L2769) and 20 U/mL of IL-2 (BD Pharmingen, Cat. #554603). After 48 h, PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation, washed with R-2 medium, and centrifuged at 450 RCF for 25 min. to remove dead cells. Next, cells from each donor were resuspended in R-10 with 20 U/mL of IL-2 and infected with a R5 HIV-1 strain (BaL) at an MOI of 10-2. After 2 h of infection at 37°C, cells were washed 3 times with R-2. Cell pellets were resuspended in R-10 with 20 U/mL of IL-2, seeded at 2 × 106 cells per well in 24-well plates, and treated with drugs at the indicated doses. Media were harvested every 2 or 3 days after infection and assayed by p24 ELISA as described. The effect of these drugs on cell viability was assessed by trypan blue stain and counted on Kova Glasstic slide 10 with grids (VWR, Cat. #CA36200-020).
Studies were funded by an operating grant from the Ontario HIV Treatment Network. We wish to thank Mario Ostrowski for providing the PBMCs used in this study.
- Stoltzfus CM, Madsen JM: Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Current HIV Research. 2006, 4 (1): 43-55. 10.2174/157016206775197655.View ArticlePubMedGoogle Scholar
- Tazi J, Bakkour N, Marchand V, Ayadi L, Aboufirassi A, Branlant C: Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action. Febs J. 2010, 277 (4): 867-876. 10.1111/j.1742-4658.2009.07522.x.View ArticlePubMedGoogle Scholar
- McLaren M, Marsh K, Cochrane A: Modulating HIV-1 RNA processing and utilization. Front Biosci. 2008, 13: 5693-5707.View ArticlePubMedGoogle Scholar
- Nekhai S, Jeang KT: Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 2006, 1: 417-426. 10.2217/174609126.96.36.1997.View ArticlePubMedGoogle Scholar
- Romani B, Engelbrecht S, Glashoff RH: Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol. 2010, 91 (Pt 1): 1-12.View ArticlePubMedGoogle Scholar
- Pollard V, Malim M: The HIV-1 Rev Protein. Ann. Rev. Microbiol. 1998, 52: 491-532. 10.1146/annurev.micro.52.1.491.View ArticleGoogle Scholar
- Hope TJ: The ins and outs of HIV Rev. Arch. Biochem. Biophys. 1999, 365: 186-191. 10.1006/abbi.1999.1207.View ArticlePubMedGoogle Scholar
- Madsen JM, Stoltzfus CM: A suboptimal 5' splice site downstream of HIV-1 splice site A1 is required for unspliced viral mRNA accumulation and efficient virus replication. Retrovirology. 2006, 3: 10-10.1186/1742-4690-3-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Kammler S, Otte M, Hauber I, Kjems J, Hauber J, Schaal H: The strength of the HIV-1 3' splice sites affects Rev function. Retrovirology. 2006, 3: 89-10.1186/1742-4690-3-89.PubMed CentralView ArticlePubMedGoogle Scholar
- Bilodeau PS, Domsic JK, Mayeda A, Krainer AR, Stoltzfus CM: RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element. J. Virol. 2001, 75 (18): 8487-8497. 10.1128/JVI.75.18.8487-8497.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Amendt B, Si Z, Stoltzfus CM: Presence of Exon Splicing Silencers within Human Immunodeficiency Virus Type 1 tat Exon 2 and tat-rev Exon 3: Evidence for Inhibition Mediated by Cellular Factors. Mol. Cell. Biol. 1995, 15: 4606-4615.PubMed CentralView ArticlePubMedGoogle Scholar
- Damgaard CK, Tange TO, Kjems J: hnRNP A1 controls HIV-1 mRNA splicing through cooperative binding to intron and exon splicing silencers in the context of a conserved secondary structure. RNA. 2002, 8: 1401-1415. 10.1017/S1355838202023075.PubMed CentralView ArticlePubMedGoogle Scholar
- Marchand V, Mereau A, Jacquenet S, Thomas D, Mougin A, Gattoni R, Stevenin J, Branlant C: A Janus splicing regulatory element modulates HIV-1 tat and rev mRNA production by coordination of hnRNP A1 cooperative binding. J. Mol. Biol. 2002, 323 (4): 629-652. 10.1016/S0022-2836(02)00967-1.View ArticlePubMedGoogle Scholar
- Zhu J, Mayeda A, Krainer A: Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell. 2001, 8 (6): 1351-1361. 10.1016/S1097-2765(01)00409-9.View ArticlePubMedGoogle Scholar
- Graveley BR: Sorting out the complexity of SR protein functions. RNA. 2000, 6 (9): 1197-1211. 10.1017/S1355838200000960.PubMed CentralView ArticlePubMedGoogle Scholar
- Hallay H, Locker N, Ayadi L, Ropers D, Guittet E, Branlant C: Biochemical and NMR study on the competition between proteins SC35, SRp40, and heterogeneous nuclear ribonucleoprotein A1 at the HIV-1 Tat exon 2 splicing site. J Biol Chem. 2006, 281 (48): 37159-37174. 10.1074/jbc.M603864200.View ArticlePubMedGoogle Scholar
- Madsen JM, Stoltzfus CM: An exonic splicing silencer downstream of the 3' splice site A2 is required for efficient human immunodeficiency virus type 1 replication. J Virol. 2005, 79 (16): 10478-10486. 10.1128/JVI.79.16.10478-10486.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Caputi M, Freund M, Kammler S, Asang C, Schaal H: A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression. J. Virol. 2004, 78 (12): 6517-6526. 10.1128/JVI.78.12.6517-6526.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Jablonski JA, Caputi M: Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. J Virol. 2009, 83 (2): 981-992. 10.1128/JVI.01801-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Ropers D, Ayadi L, Gattoni R, Jacquenet S, Damier L, Branlant C, Stevenin J: Differential effects of the SR proteins 9G8, SC35, ASF/SF2 and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA. J Biol Chem. 2004, 279: 29963-29973. 10.1074/jbc.M404452200.View ArticlePubMedGoogle Scholar
- Jacquenet S, Decimo D, Muriaux D, Darlix JL: Dual effect of the SR proteins ASF/SF2, SC35 and 9G8 on HIV-1 RNA splicing and virion production. Retrovirology. 2005, 2 (1): 33-10.1186/1742-4690-2-33.PubMed CentralView ArticlePubMedGoogle Scholar
- Ryo A, Suzuki Y, Arai M, Kondoh N, Wakatsuki T, Hada A, Shuda M, Tanaka K, Sato C, Yamamoto M, et al: Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res Hum Retroviruses. 2000, 16 (10): 995-1005. 10.1089/08892220050058416.View ArticlePubMedGoogle Scholar
- Maldarelli F, Xiang C, Chamoun G, Zeichner SL: The expression of the essential nuclear splicing factor SC35 is altered by human immunodeficiency virus infection. Virus Res. 1998, 53 (1): 39-51. 10.1016/S0168-1702(97)00130-5.View ArticlePubMedGoogle Scholar
- Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Hagiwara M: Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci USA. 2006, 103 (30): 11329-11333. 10.1073/pnas.0604616103.PubMed CentralView ArticlePubMedGoogle Scholar
- Stojdl DF, Bell JC: SR protein kinases: the splice of life. Biochem Cell Biol. 1999, 77 (4): 293-298. 10.1139/o99-046.View ArticlePubMedGoogle Scholar
- Bullock AN, Das S, Debreczeni JE, Rellos P, Fedorov O, Niesen FH, Guo K, Papagrigoriou E, Amos AL, Cho S, et al: Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure. 2009, 17 (3): 352-362. 10.1016/j.str.2008.12.023.PubMed CentralView ArticlePubMedGoogle Scholar
- Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, Ghosh G: Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell. 2005, 20 (1): 77-89. 10.1016/j.molcel.2005.08.025.View ArticlePubMedGoogle Scholar
- Colwill K, Feng LL, Yeakley JM, Gish GD, Caceres JF, Pawson T, Fu XD: SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. J Biol Chem. 1996, 271 (40): 24569-24575. 10.1074/jbc.271.40.24569.View ArticlePubMedGoogle Scholar
- Velazquez-Dones A, Hagopian JC, Ma CT, Zhong XY, Zhou H, Ghosh G, Fu XD, Adams JA: Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. J Biol Chem. 2005, 280 (50): 41761-41768. 10.1074/jbc.M504156200.View ArticlePubMedGoogle Scholar
- Nayler O, Schnorrer F, Stamm S, Ullrich A: The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation. J Biol Chem. 1998, 273 (51): 34341-34348. 10.1074/jbc.273.51.34341.View ArticlePubMedGoogle Scholar
- Duncan PI, Stojdl DF, Marius RM, Bell JC: In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Mol Cell Biol. 1997, 17 (10): 5996-6001.PubMed CentralView ArticlePubMedGoogle Scholar
- Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC: The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing. Exp Cell Res. 1998, 241 (2): 300-308. 10.1006/excr.1998.4083.View ArticlePubMedGoogle Scholar
- Koizumi J, Okamoto Y, Onogi H, Mayeda A, Krainer AR, Hagiwara M: The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs). J Biol Chem. 1999, 274 (16): 11125-11131. 10.1074/jbc.274.16.11125.View ArticlePubMedGoogle Scholar
- Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H, et al: Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004, 279 (23): 24246-24254. 10.1074/jbc.M314298200.View ArticlePubMedGoogle Scholar
- Younis I, Berg M, Kaida D, Dittmar K, Wang C, Dreyfuss G: Rapid-response splicing reporter screens identify differential regulators of constitutive and alternative splicing. Mol Cell Biol. 2010, 30 (7): 1718-1728. 10.1128/MCB.01301-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, Duncan PI: The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. Embo J. 1996, 15 (2): 265-275.PubMed CentralPubMedGoogle Scholar
- Gui JF, Tronchere H, Chandler SD, Fu XD: Purification and characterization of a kinase specific for the serine- and arginine-rich pre-mRNA splicing factors. Proc Natl Acad Sci USA. 1994, 91 (23): 10824-10828. 10.1073/pnas.91.23.10824.PubMed CentralView ArticlePubMedGoogle Scholar
- Nayler O, Stamm S, Ullrich A: Characterization and comparison of four serine- and arginine-rich (SR) protein kinases. Biochem J. 1997, 326 (Pt 3): 693-700.PubMed CentralView ArticlePubMedGoogle Scholar
- Nikolakaki E, Simos G, Georgatos SD, Giannakouros T: A nuclear envelope-associated kinase phosphorylates arginine-serine motifs and modulates interactions between the lamin B receptor and other nuclear proteins. J Biol Chem. 1996, 271 (14): 8365-8372. 10.1074/jbc.271.14.8365.View ArticlePubMedGoogle Scholar
- Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, Tazi J: Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 1996, 381 (6577): 80-82. 10.1038/381080a0.View ArticlePubMedGoogle Scholar
- Zhou X, Vink M, Berkhout B, Das AT: Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control. Retrovirology. 2006, 3: 82-10.1186/1742-4690-3-82.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhou X, Vink M, Klaver B, Verhoef K, Marzio G, Das AT, Berkhout B: The genetic stability of a conditional live HIV-1 variant can be improved by mutations in the Tet-On regulatory system that restrain evolution. J Biol Chem. 2006, 281 (25): 17084-17091. 10.1074/jbc.M513400200.View ArticlePubMedGoogle Scholar
- Yeakley JM, Tronchere H, Olesen J, Dyck JA, Wang HY, Fu XD: Phosphorylation regulates in vivo interaction and molecular targeting of serine/arginine-rich pre-mRNA splicing factors. J Cell Biol. 1999, 145 (3): 447-455. 10.1083/jcb.145.3.447.PubMed CentralView ArticlePubMedGoogle Scholar
- Xiao SH, Manley JL: Phosphorylation of the ASF/SF2 RS domain affects both protein-protein and protein-RNA interactions and is necessary for splicing. Genes Dev. 1997, 11 (3): 334-344. 10.1101/gad.11.3.334.View ArticlePubMedGoogle Scholar
- Prasad J, Colwill K, Pawson T, Manley JL: The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing. Mol Cell Biol. 1999, 19 (10): 6991-7000.PubMed CentralView ArticlePubMedGoogle Scholar
- Eisenreich A, Bogdanov VY, Zakrzewicz A, Pries A, Antoniak S, Poller W, Schultheiss HP, Rauch U: Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res. 2009, 104 (5): 589-599. 10.1161/CIRCRESAHA.108.183905.View ArticlePubMedGoogle Scholar
- Hartmann AM, Rujescu D, Giannakouros T, Nikolakaki E, Goedert M, Mandelkow EM, Gao QS, Andreadis A, Stamm S: Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol Cell Neurosci. 2001, 18 (1): 80-90. 10.1006/mcne.2001.1000.View ArticlePubMedGoogle Scholar
- Yomoda J, Muraki M, Kataoka N, Hosoya T, Suzuki M, Hagiwara M, Kimura H: Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells. 2008, 13 (3): 233-244. 10.1111/j.1365-2443.2008.01163.x.View ArticlePubMedGoogle Scholar
- Rodgers JT, Haas W, Gygi SP, Puigserver P: Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis. Cell Metab. 2010, 11 (1): 23-34. 10.1016/j.cmet.2009.11.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Stoilov P, Daoud R, Nayler O, Stamm S: Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. Human Molecular Genetics. 2004, 13 (5): 509-524. 10.1093/hmg/ddh051.View ArticlePubMedGoogle Scholar
- Kojima T, Zama T, Wada K, Onogi H, Hagiwara M: Cloning of human PRP4 reveals interaction with Clk1. J Biol Chem. 2001, 276 (34): 32247-32256. 10.1074/jbc.M103790200.View ArticlePubMedGoogle Scholar
- Moeslein FM, Myers MP, Landreth GE: The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B. J Biol Chem. 1999, 274 (38): 26697-26704. 10.1074/jbc.274.38.26697.View ArticlePubMedGoogle Scholar
- Flexner C: HIV drug development: the next 25 years. Nat Rev Drug Discov. 2007, 6 (12): 959-966. 10.1038/nrd2336.View ArticlePubMedGoogle Scholar
- Jost LM, Kirkwood JM, Whiteside TL: Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods. 1992, 147 (2): 153-165.View ArticlePubMedGoogle Scholar
- Purcell D, Martin MA: Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993, 67: 6365-6378.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.